Back to Results

Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on identifying, developing, and commercializing prescription medicines in the United States, Europe, and other international markets. Its commercial portfolio includes therapies for narcolepsy and idiopathic hypersomnia, epilepsy and seizure disorders, certain cancers, and severe veno-occlusive disease. Key marketed products include Xywav, Epidiolex, Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, and Defitelio. The company also advances several pipeline programs, including Zanidatamab, Dordaviprone, Vyxeos, JZP3507, JZP815, JZP898, and JZP047, across a range of oncology and neurological indications. Founded in 2003, Jazz Pharmaceuticals plc is headquartered in Dublin, Ireland, and maintains licensing and collaboration agreements with several biotechnology and pharmaceutical partners.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-JAZZ
$238.33
-1.1% Downside
Fair
$290.60
20.6% Upside
Undervalued
Great
0.0%
November 11, 2026
16.8x
3.3x
3.4x
15.628 B
18.052 B
21.8%
97.0%
8.5
169.2%
Valuation • Fair Value

Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) Fair Value by Valuation Model

Review the available estimates for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ), including Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$238.33

Estimated downside of 1.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$160.80

Classic Ben Graham valuation formula reference.

EPV Fair Value

$239.72

Earnings power value estimate.

Comps Fair Value

$238.10

Comparable-company valuation reference.

Analyst Price Target

$290.60

Analysts imply upside of 20.6%.

How to read these valuation models

Use the 6 available valuation references for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

4.601 B

Current operating scale indicator.

Revenue Forecast

4.717 B

Forward revenue estimate.

EBITDA

1.927 B

Current operating profitability reference.

EBITDA Forecast

2.171 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.52

No elevated caution signal from this screen.

Altman Z-Score

8.5

Relatively strong balance-sheet zone.

FCF / Net Income

169.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

54

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) Stock Forecast & Technical Outlook

Review Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) has a Strong Buy consensus, with 11 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 11
Hold 2
Sell 0
FAQ • Fast Investor Answers

Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) Stock FAQ

Data-supported answers about Jazz Pharmaceuticals PLC (NASDAQ-JAZZ), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$238.33
Estimated downside 1.1%
Valuation Rating
Near Fair Value
Price is close to fair value
Analyst Target
$290.60
Implied upside 20.6%
Financial Health
Great
Current financial-health read

The current fair value estimate for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is $238.33. This implies an estimated downside of 1.1% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The available analyst price target for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is $290.60. The analyst target implies estimated upside of 20.6%.

The current financial health read for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is November 11, 2026.

The latest available data indicates no current dividend yield for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ).

The current P/E ratio listed for Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is 16.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Jazz Pharmaceuticals PLC is 15.628 B.

The current enterprise value listed for Jazz Pharmaceuticals PLC is 18.052 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Jazz Pharmaceuticals PLC is NASDAQ-JAZZ, and the stock is listed on NASDAQ.

Jazz Pharmaceuticals PLC (NASDAQ-JAZZ) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Jazz Pharmaceuticals PLC is 21.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Jazz Pharmaceuticals PLC is 97.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B
BLTE NASDAQ Belite Bio Inc ADR Fair Value Fair Market Cap 6.885 B